Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG
- Status
- recruiting
- Phase
- Phase 1
- Institution
- University of Wisconsin, Madison
- Principal investigator
- Charles Raison, MD
- Start date
- 2025-08-07
- End date
- 2027-12-01
- Registry ID
- NCT06692192
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.